May 19, 2020
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
May 19, 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Mar 26, 2020
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
Feb 18, 2020
m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil
Feb 13, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Jan 08, 2020
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
Dec 09, 2019
Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections
Dec 09, 2019
Autoimmune Technologies Announces New Subsidiary to Develop Novel Antibody and Allogeneic Somatic Stem Cell Therapeutics For the Treatment of Invasive Candidiasis and Other Infectious Disease
Nov 14, 2019
SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States
Nov 12, 2019
SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Oct 02, 2019
SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Sep 24, 2019
Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)
Sep 16, 2019
Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
Aug 12, 2019
AMA Grants MycoDART CPT Code For Its Life-Saving Test
Jul 10, 2019
New FDA-Cleared Microbicidal Liquid Kills Deadly, Drug-Resistant Candida Auris Superbug on Contact
Jun 25, 2019
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
May 13, 2019
Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris
May 06, 2019
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Apr 22, 2019
Diagnostics Company Launches New Molecular Test to Identify Deadly Superbug, Candida auris.